Kezar Life Sciences stock exits Nasdaq after merger

Kezar Life Sciences stock last traded at USD 7.29 on Nasdaq on May 11, 2026 at 4:00 p.m. ET, the same as the prior close. The company then moved through a cash and stock merger that changed the status of its Nasdaq listing.

Merger changes the listing

According to TradingView on May 11, 2026, Kezar notified Nasdaq that its merger had closed and requested suspension of trading and the filing of Form 25 to delist and deregister its shares. The surviving corporation also planned to terminate its reporting obligations under Sections 13 and 15(d).

The transaction terms provide the key investor reference point. StockTitan reports that Kezar agreed to a tender offer of USD 6.955 per share in cash plus one contingent value right per share.

Losses narrowed in Q1 2026

Kezar reported a Q1 2026 net loss of USD 5.8 million, down from USD 16.6 million a year earlier, while research and development spending fell to USD 1.5 million after trial terminations and a 70 percent workforce reduction, according to StockTitan.

Cash and cash equivalents were USD 66.2 million as of March 31, 2026. Management said that balance would fund operations for at least 12 months, making liquidity the central financial measure as the merger reshaped the company.

Last quote and company profile

The last quoted USD 7.29 price on May 11, 2026 stood 3.44 percent below the 52-week high of USD 7.55 and 106.52 percent above the low of USD 3.53. Market capitalization was USD 53.9 million on that date.